Clozapine use reduced psychiatric hospitalization and emergency room visits in patients with bipolar disorder independent of improved treatment regularity in a three-year follow-up period

Bipolar Disorders

Volumn 17, Issue 4, 2015, Pages 415-423

  Wu, Chi Shin ^a,b   Wang, Sheng Chang ^c   Liu, Shi Kai ^d,e  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bipolar disorder; Clozapine; Hospitalization; Medication possession ratio (MPR); Treatment regularity

Indexed keywords

CLOZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BIPOLAR DISORDER; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG USE; EMERGENCY TREATMENT; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; TAIWANESE; TREATMENT OUTCOME; AGED; EMERGENCY HEALTH SERVICE; MEDICATION COMPLIANCE; MIDDLE AGED; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; TAIWAN; UTILIZATION; UTILIZATION REVIEW;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CLOZAPINE; EMERGENCY SERVICE, HOSPITAL; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MEDICATION ADHERENCE; MIDDLE AGED; TAIWAN; UTILIZATION REVIEW;

EID: 84930413568     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12261     Document Type: Article

References (37)

1. Gupta M. Clozapine monotherapy for 66 months in treatment resistant bipolar disorder: a case report. J Clin Psychopharmacol 2009; 29: 501-503.
2. Chang JS, Ha KS, Young Lee K, Sik Kim Y, Min Ahn Y. The effects of long-term clozapine add-on therapy on the rehospitalization rate and the mood polarity patterns in bipolar disorders. J Clin Psychiatry 2006; 67: 461-467.
3. Chen CK, Shiah IS, Yeh CB, Mao WC, Chang CC. Combination treatment of clozapine and topiramate in resistant rapid-cycling bipolar disorder. Clin Neuropharmacol 2005; 28: 136-138.
4. Ciapparelli A, Dell'Osso L, Pini S, Chiavacci MC, Fenzi M, Cassano GB. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. J Clin Psychiatry 2000; 61: 329-334.
5. Chanpattana W. Combined ECT and clozapine in treatment-resistant mania. J ECT 2000; 16: 204-207.
6. Zarate CA Jr, Tohen M, Banov MD, Weiss MK, Cole JO. Is clozapine a mood stabilizer? J Clin Psychiatry 1995; 56: 108-112.
7. Banov MD, Zarate CA Jr, Tohen M et al. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry 1994; 55: 295-300.
8. Suppes T, Ozcan ME, Carmody T. Response to clozapine of rapid cycling versus non-cycling patients with a history of mania. Bipolar Disord 2004; 6: 329-332.
9. Calabrese JR, Kimmel SE, Woyshville MJ et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996; 153: 759-764.
10. Green AI, Tohen M, Patel JK et al. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry 2000; 157: 982-986.
11. Masi G, Mucci M, Millepiedi S. Clozapine in adolescent inpatients with acute mania. J Child Adolesc Psychopharmacol 2002; 12: 93-99.
12. Fehr BS, Ozcan ME, Suppes T. Low doses of clozapine may stabilize treatment-resistant bipolar patients. Eur Arch Psychiatry Clin Neurosci 2005; 255: 10-14.
13. Nielsen J, Kane JM, Correll CU. Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study. Bipolar Disord 2012; 14: 863-869.
14. Nielsen J, Nielsen RE, Correll CU. Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. J Clin Psychopharmacol 2012; 32: 678-683.
15. Ciapparelli A, Dell'Osso L, Bandettini di Poggio A et al. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry 2003; 64: 451-458.
16. Brambilla P, Barale F, Soares JC. Atypical antipsychotics and mood stabilization in bipolar disorder. Psychopharmacology 2003; 166: 315-332.
17. Fountoulakis KN, Kasper S, Andreassen O et al. Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci 2012; 262 (Suppl. 1): 1-48.
18. Yildiz A, Vieta E, Leucht S, Baldessarini RJ. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology 2011; 36: 375-389.
19. Meltzer HY, Cola PA. The pharmacoeconomics of clozapine: a review. J Clin Psychiatry 1994; 55 (Suppl. B): 161-165.
20. Patel NC, Crismon ML, Miller AL, Johnsrud MT. Drug adherence: effects of decreased visit frequency on adherence to clozapine therapy. Pharmacotherapy 2005; 25: 1242-1247.
21. Wu CS, Desarkar P, Palucka A, Lunsky Y, Liu SK. Acute inpatient treatment, hospitalization course and direct costs in bipolar patients with intellectual disability. Res Dev Disabil 2013; 34: 4062-4072.
22. Tang CH, Hsieh MH, Hung ST, Lee IH, Lin YJ, Yang YK. One-year post-hospital medical costs and relapse rates of bipolar disorder patients in Taiwan: a population-based study. Bipolar Disord 2010; 12: 859-865.
23. Stokes ME, Davis CS, Koch GG. Categorical Data Analysis Using the SAS System, 2nd edn. Cary, NC: SAS Institute Inc., 2000.
24. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999; 156: 1164-1169.
25. Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists' attitude towards and knowledge of clozapine treatment. J Psychopharmacol 2010; 24: 965-971.
26. Goldberg JF, Harrow M. Consistency of remission and outcome in bipolar and unipolar mood disorders: a 10-year prospective follow-up. J Affect Disord 2004; 81: 123-131.
27. Osby U, Tiainen A, Backlund L et al. Psychiatric admissions and hospitalization costs in bipolar disorder in Sweden. J Affect Disord 2009; 115: 315-322.
28. Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry 2013; 12: 216-226.
29. Colom F, Vieta E, Martinez-Aran A et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003; 60: 402-407.
30. Chiles JA, Davidson P, McBride D. Effects of clozapine on use of seclusion and restraint at a state hospital. Hosp Community Psychiatry 1994; 45: 269-271.
31. Smith H, White T. The effect of clozapine on the social behaviour schedule in patients attending a forensic psychiatry day hospital. Med Sci Law 2004; 44: 213-216.
32. Citrome L, Volavka J, Czobor P et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 2001; 52: 1510-1514.
33. Chengappa KN, Vasile J, Levine J et al. Clozapine: its impact on aggressive behavior among patients in a state psychiatric hospital. Schizophr Res 2002; 53: 1-6.
34. Suppes T, McElroy SL, Gilbert J, Dessain EC, Cole JO. Clozapine in the treatment of dysphoric mania. Biol Psychiatry 1992; 32: 270-280.
35. McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 2005; 66 (Suppl. 3): 28-36.
36. Latimer E, Wynant W, Clark R et al. Underprescribing of clozapine and unexplained variation in use across hospitals and regions in the Canadian province of Quebec. Clin Schizophr Relat Psychoses 2013; 7: 33-41.
37. Fitton A, Benfield P. Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia. Pharmacoeconomics 1993; 4: 131-156.